Guest Editorial

OPEN ACCESS

Bridging Blood and Genes: The Future of Transfusion Medicine and Molecular Biology

Usman Waheed[1], Ahmad Farooq[2]

[1]Department of Allied Health Sciences, Islamabad Medical and Dental College, Islamabad, Pakistan
[2]Clinical Trials Unit, Dr. Akbar Niazi Teaching Hospital, Islamabad, Pakistan

Address of Correspondent
Usman Waheed, Ph.D.
Department of Allied Health Sciences
Islamabad Medical and Dental College
Islamabad, Pakistan
E: drusman.waheed1@gmail.com
https://orcid.org/0000-0002-5760-5671

Cite this editorial as: Waheed U, Farooq A. Bridging Blood and Genes: The Future of Transfusion Medicine and Molecular Biology. Ann Pak Inst Med Sci. 2024;20(Suppl. 2):808-810. doi: 10.48036/apims.v20iSuppl.2.1282.

Transfusion medicine has long been a cornerstone of modern healthcare, ensuring that patients in need receive safe, compatible blood and blood components. Over the past three decades, transfusion medicine has experienced significant progress, primarily fueled by breakthroughs in molecular biology. This field, once primarily focused on serological testing for blood groups and cross-matching and the screening for transfusion-transmitted infections, now benefits from cutting-edge technologies that improve safety, efficiency, and precision. The introduction of molecular techniques has overcome many of these obstacles, enhancing precision and broadening the scope for personalized patient care.

Limitations of Traditional Serological Testing in Blood Banks

Serological testing, which relies on haemagglutination reactions between antigens on red blood cells and antisera or plasma antibodies with reagent red blood cells, has been the cornerstone of transfusion medicine and blood bank laboratories. While these tests have been indispensable, they come with inherent limitations. The process is subject to technical constraints such as limited availability of specific antisera and subjective interpretation of results, which can vary depending on the skill and experience of the laboratory professional.[1] Further, serological testing can be complicated by factors such as autoantibodies, interference from monoclonal antibody treatments, or recent blood transfusions that mask true blood type results.[2]

Molecular Genotyping: A Game-Changer

To address these challenges, molecular testing has emerged as a highly accurate alternative for blood typing and patient-donor compatibility testing. The application of molecular biology has revolutionized the way blood is typed, screened, and managed. Molecular genotyping leverages the analysis of DNA to pinpoint genetic variations and determine blood group antigens at a more granular level.[3] When conventional serological tests yield inconclusive results, especially for ABO and Rh blood groups, molecular genotyping steps in as a reliable solution to establish precise blood group typing. Molecular genotyping is particularly advantageous for detecting variant expressions in blood group alleles that may not be apparent through haemagglutination.[4] For instance, individuals with weak or partial D antigen expression can be at risk for alloimmunization if misclassified as Rh(D)-positive or -negative.[5] Point mutations in the RHD gene can lead to phenotypes such as weak D (non-types 1, 2, or 3) or partial D, which traditional methods cannot always differentiate.[6] Molecular analysis of the RHD gene allows for accurate classification, ensuring that Rh(D)-negative individuals who need Rh immunoglobulin prophylaxis are properly identified to prevent haemolytic disease of the foetus and newborn.

Techniques in Molecular Genotyping

Early methods of ABO genotyping included restriction fragment length polymorphism (RFLP) PCR, where enzymes identify alleles by fragmenting DNA at specific sequences.[7] This was followed by the development of allele-specific primers, facilitating sequence-specific primer PCR and multiplex PCR methods. These processes use gel or capillary electrophoresis to detect DNA amplicons. Real-time PCR (qPCR) advanced the field by enabling the detection of DNA amplicons in real-time using fluorescent probes, thereby speeding up the process.[8] Despite the accuracy of PCR-based techniques, they remain labour-intensive and have relatively slow turnaround times compared to newer technologies. However, their ability to deliver precise genotyping has made them essential, particularly for cases involving rare blood types or complex transfusion requirements. Newer assays such as loop-mediated isothermal amplification (LAMP) and multiplex real-time polymerase chain reaction (PCR), are also increasingly being used for the rapid genotyping of ABO blood groups.[9] LAMP offers a quick and efficient approach that amplifies DNA under isothermal conditions, providing rapid results with minimal equipment. Multiplex real-time PCR, on the other hand, enables simultaneous detection of multiple target genes in a single reaction, improving the speed and accuracy of genotyping. These methods represent significant strides in transfusion medicine by facilitating faster and more precise blood group determination.

Molecular Testing for Infectious Disease Screening

Another critical application of molecular biology in transfusion medicine is screening for infectious diseases. Nucleic acid testing (NAT) has become a mainstay in screening blood donations for pathogens such as HIV, hepatitis B and C, and other transfusion-transmissible infections.[10,11] NAT is highly sensitive and can detect viral nucleic acids even in the early "window period" when antibodies or antigens are not yet present in detectable quantities.[12] This significantly reduces the risk of transfusion-transmitted infections and enhances the overall safety of blood supplies.[13]

Challenges in Implementing Molecular Techniques

While the benefits of molecular testing are clear, its integration into routine transfusion medicine practices faces several hurdles. One of the primary challenges is the cost associated with the acquisition and maintenance of molecular testing platforms, which can be prohibitive for many facilities.[14] Additionally, these tests require specialized technical expertise, making their implementation more feasible in reference blood bank laboratories rather than in smaller or less-equipped clinical settings. Technical issues such as false positives or false negatives may also occur (although rare), impacting patient care. The variability in blood group genetics, including large deletions, hybrid alleles, and silent alleles, can lead to misinterpretation of phenotypes if not carefully managed.[15,16] Accurate interpretation requires a deep understanding of the underlying genetic architecture and continuous validation of testing protocols.

Future Directions: Next-Generation Sequencing and Beyond

The future of molecular biology in transfusion medicine is promising, with new technologies poised to further revolutionize the field. Next-generation sequencing (NGS) holds significant potential for enhancing the throughput of blood donor genotyping, enabling comprehensive screening for rare blood group antigens.[17] This can be particularly beneficial for patients with complex transfusion needs, such as those with chronic transfusion requirements or who belong to ethnically diverse populations with unique blood group alleles. NGS also offers the capability to develop targeted panels tailored to specific genetic variations found in particular populations.[18] This customization could streamline the process of finding compatible blood donors and reduce the risk of alloimmunization in patients who receive frequent transfusions, e.g. thalassaemics. Further, advancements in data analysis and bioinformatics are expected to support more efficient interpretation of genotyping results, addressing some of the current challenges in phenotypic prediction.[19]

Broader Applications and Implications

Beyond just typing and matching, molecular biology is also contributing to the development of novel therapies in transfusion medicine.[20] Research into the genetic regulation of blood group antigens and the molecular mechanisms underlying alloimmunization is paving the way for potential gene-editing strategies and biotherapeutics that could minimize the risks associated with transfusions.[21] The application of CRISPR-Cas9 technology, for instance, may offer future possibilities in modifying donor red blood cells to eliminate antigens that commonly lead to immune responses.[22]

Conclusion

The role of molecular biology in transfusion medicine is profound and continues to expand, addressing the limitations of traditional serological methods and enhancing patient care. From improving blood type accuracy to enabling sophisticated screening for transfusion-transmitted infectious diseases, molecular techniques have proven indispensable. Although challenges remain, advancements such as next-generation sequencing promise to overcome current limitations and set the stage for more personalized and effective transfusion practices. The growing integration of these technologies indicates a new era in transfusion medicine, one marked by precision, safety, and improved patient outcomes.

References

1. Yovdiy AV, Butina EV, Poponina EA, Zaitseva GA, Minaeva NV. Interpretation of the results of immunohematological tests in hematological patients. Klin Lab Diagn. 2019;64(4):221-224. https://doi.org/10.18821/0869-2084-2019-64-4-221-224.
2. Möhnle P, Humpe A, Wittmann G. When A is not A anymore: problems and pitfalls with blood group typing. Anaesthesist. 2018;67(9):637-646. https://doi.org/10.1007/s00101-018-0483-9.
3. Gorakshakar A, Gogri H, Ghosh K. Evolution of technology for molecular genotyping in blood group systems. Indian J Med Res. 2017;146(3):305-315. doi: 10.4103/ijmr.IJMR_914_16.
4. Westhoff CM. Blood group genotyping. Blood. 2019;133(17):1814-1820. https://doi.org/10.1182/blood-2018-11-833954.
5. Kulkarni S, Choudhary B, Gogri H, Patil S, Manglani M, Sharma R, Madkaikar M. Molecular genotyping of clinically important blood group antigens in patients with thalassaemia. Indian J Med Res. 2018;148(6):713-720. https://doi.org/10.4103/ijmr.IJMR_455_17.
6. Ying Y, Zhang J, Hong X, Xu X, He J, Zhu F. The significance of *RHD* genotyping and characteristic analysis in Chinese RhD variant individuals. Front Immunol. 2021;12:755661. https://doi.org/10.3389/fimmu.2021.755661.
7. Mifsud NA, Haddad AP, Condon JA, Sparrow RL. ABO genotyping by polymerase chain reaction-restriction fragment length polymorphism. Immunohematology. 1996;12(4):143-148.
8. Liu Z, Liu M, Mercado T, Illoh O, Davey R. Extended blood group molecular typing and next-generation sequencing. Transfus Med Rev. 2014;28(4):177-186. https://doi.org/10.1016/j.tmrv.2014.08.003.
9. Choi H, Choi J, Kwak K, Kim Y, Kim E, Lim SK. Rapid ABO genotyping method using loop-mediated isothermal amplification (LAMP) and real-time PCR. Int J Legal Med. 2024;138(3):751-756. https://doi.org/10.1007/s00414-023-03144-5.
10. Faddy HM, Osiowy C, Custer B, Busch M, Stramer SL, Adesina O, et al; Virology and Surveillance; Risk Assessment and Policy subgroups of the ISBT Working Party on Transfusion-transmitted Infectious Diseases. International review of blood donation nucleic acid amplification testing. Vox Sang. 2024;119(4):315-325. https://doi.org/10.1111/vox.13592.
11. Tanaka A, Matsubayashi K, Odajima T, Sakata H, Iida J, Kai K, et al. Universal nucleic acid donor screening revealed epidemiological features of hepatitis E and prevented transfusion-transmitted infection in Japan. Transfusion. 2024;64(2):335-347. https://doi.org/10.1111/trf.17696.
12. Dutch M, Cheng A, Kiely P, Seed C. Revised nucleic acid test window periods: Applications and limitations in organ donation practice. Transpl Infect Dis. 2024;26(1):e14180. https://doi.org/10.1111/tid.14180.
13. Ye X, Xiong W, Xu X, Zeng J, Xie H, Li B, He B, Chen L, Mo Q. Cost-benefit analysis of serological and nucleic acid testing for hepatitis B virus in blood donors in southern China. BMC Infect Dis. 2024;24(1):909. https://doi.org/10.1186/s12879-024-09786-z.
14. Anne PB, Gupta A, Misra S, Sharma SK, Garg MK, Bajpayee A, Bundas S, Bohra M, Asirvatham V. Economic Evaluation of Nucleic Acid Testing for Screening of Blood Donations for Thalassemia Patients (ECONAT) in Western India. Indian J Hematol Blood Transfus. 2023;39(2):317-324. https://doi.org/10.1007/s12288-022-01564-8.
15. Gueuning M, Thun GA, Wittig M, Galati AL, Meyer S, Trost N, et al. Haplotype sequence collection of ABO blood group alleles by long-read sequencing reveals putative A1-diagnostic variants. Blood Adv. 2023;7(6):878-892. https://doi.org/10.1182/bloodadvances.
16. Srivastava K, Bueno MU, Flegel WA. Breakpoint regions of an RHD-CE(4-9)-D allele and a rare JK allele in a Pacific Islander individual. Blood Transfus. 2024;22(3):189-197. https://doi.org/10.2450/BloodTransfus.534.
17. Matosinho CGR, Silva CGR, Martins ML, Silva-Malta MCF. Next Generation Sequencing of red blood cell antigens in transfusion medicine: Systematic review and meta-analysis. Transfus Med Rev. 2024;38(1):150776. https://doi.org/10.1016/j.tmrv.2023.150776.
18. Antúnez-Rodríguez A, García-Rodríguez S, Pozo-Agundo A, Sánchez-Ramos JG, Moreno-Escobar E, Triviño-Juárez JM, et al. Targeted next-generation sequencing panel to investigate antiplatelet adverse reactions in acute coronary syndrome patients undergoing percutaneous coronary intervention with stenting. Thromb Res. 2024;240:109060. https://doi.org/10.1016/j.thromres.2024.109060.
19. Satam H, Joshi K, Mangrolia U, Waghoo S, Zaidi G, Rawool S, Thakare RP, Banday S, Mishra AK, Das G, Malonia SK. Next-Generation Sequencing Technology: Current trends and advancements. Biology (Basel). 2023;12(7):997. https://doi.org/10.3390/biology12070997.
20. Christakopoulos GE, Telange R, Yen J, Weiss MJ. Gene Therapy and Gene Editing for β-Thalassemia. Hematol Oncol Clin North Am. 2023;37(2):433-447. https://doi.org/10.1016/j.hoc.2022.12.012.
21. Song X, Liu J, Chen T, Zheng T, Wang X, Guo X. Gene therapy and gene editing strategies in inherited blood disorders. J Genet Genomics. 2024;51(11):1162-1172. https://doi.org/10.1016/j.jgg.2024.07.004.
22. Hu J, Zhong Y, Xu P, Xin L, Zhu X, Jiang X, Gao W, Yang B, Chen Y. β-Thalassemia gene editing therapy: Advancements and difficulties. Medicine (Baltimore). 2024;103(18):e38036. https://doi.org/10.1097/MD.0000000000038036.